OPKO Health Q2 2026: Narrowed Loss, Pipeline Momentum, and Full-Year Guidance
OPK sits 47% above its 52-week low of $0.977.
Summary
OPKO Health posted Q2 2026 revenue of $163.5 million and a net loss of just $8.4 million, a dramatic improvement from the prior year. The company also issued full-year revenue guidance of $560–$585 million and highlighted progress across its clinical pipeline, including three new Phase 1 trials.
Key Events · Earnings and Guidance · OPK
-
Q2 Loss Narrows Sharply
Net loss improved to $8.4 million ($0.01/share) from $148.4 million ($0.19/share) in Q2 2025, driven by a $29.4 million IP revenue boost from the Nicoya amendment and an $18.1 million Labcorp earnout.
-
Full-Year Revenue Guidance Issued
OPKO guided for 2026 total revenue of $560–$585 million, with services revenue of $296–$306 million, product revenue of $164–$174 million, and IP/other revenue of $100–$105 million.
-
Pipeline Advances with Three Phase 1 Starts
MDX2003 (B-cell lymphoma), MDX2301 (COVID-19 prevention, BARDA-funded), and OPK-88006 (MASH) all initiated Phase 1 trials, with initial data expected in late 2026 or early 2027.
-
Nicoya Deal Amended for Equity Stake
OPKO received a 15% equity stake in Nicoya in exchange for revised royalties, while retaining up to $115 million in milestones; the deal also recognized $29.4 million in Q2 IP revenue.
Analysis · OPK · Life Sciences
A significantly improved second quarter saw OPKO Health's net loss shrink to $8.4 million from $148.4 million a year ago, fueled by higher intellectual property revenue and an $18.1 million earnout from the Labcorp asset sale. Full-year 2026 revenue guidance of $560–$585 million underscores confidence in the commercial trajectory. Meanwhile, multiple clinical programs advanced—Phase 1 initiations for MDX2003, MDX2301, and OPK-88006—and the amended Nicoya deal delivered a 15% equity stake while preserving up to $115 million in milestones. With $314.4 million in cash and an active share buyback, the company is balancing pipeline investment with shareholder returns.
At the time of this filing, OPK was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $936.3M. The 52-week trading range was $0.98 to $1.61. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.